1/21
Vocabulary flashcards covering typical and atypical antipsychotics, SAR, pharmacokinetics, side effects, and antimanic agents from PHAR 441 lecture.
Psychosis
Mental disorders involving a loss of contact with reality that affect approximately 1% of people, pathologically linked to the over-activity of dopaminergic neurons in the brain.
Typical Antipsychotic Agents
First-generation neuroleptic drugs (e.g., Phenothiazines and Butyrophenones) that primarily function by blocking dopamine receptors, particularly postsynaptic D2 receptors in the mesolimbic pathway.
Extrapyramidal Side Effects (EPS)
Movement disorders caused by dopamine receptor blockade in the nigrostriatal pathway, commonly associated with typical antipsychotics and including acute dystonia and tardive dyskinesia.
Acute Dystonia
An extrapyramidal side effect characterized by involuntary movements such as muscle spasms and a protruding tongue, typically occurring within the first few weeks of treatment and declining over time.
Tardive Dyskinesia
An extrapyramidal side effect characterized by impairment of voluntary movements, frequently affecting the face and tongue, which develops over months to years of antipsychotic treatment and is often irreversible.

Phenothiazines
A class of typical antipsychotics with a tricyclic 6-6-6 system in which two benzene rings are linked by sulfur and nitrogen atoms, requiring an unbranched 3-carbon chain between the two nitrogen atoms for optimal antipsychotic activity.
Chlorpromazine
A low-potency typical phenothiazine antipsychotic (t1/2=15 to 30hours) with low EPS incidence, significant sedative and hypotensive properties, and an indication for symptomatic relief of nausea, vomiting, and hiccups.

Piperidine Phenothiazine Subgroup
A subgroup of phenothiazines containing a six-membered saturated ring with one nitrogen atom, associated with lower EPS, high anticholinergic activity, and sedative/hypnotic properties.
Thioridazine
A piperidine subgroup phenothiazine (t1/2=7 to 13hours) featuring low EPS and high anticholinergic activity, which can cause pigmentary retinopathy at high doses.
Mesoridazine
The active S-oxidation metabolite of thioridazine (t1/2=24 to 48hours) that shares thioridazine's clinical properties but does not cause pigmentary retinopathy.

Piperazine Phenothiazine Subgroup
A subgroup of phenothiazines featuring a six-membered ring with two nitrogen atoms; it minimizes anticholinergic side effects relative to other subgroups but carries a higher risk of EPS.
Fluphenazine
The most potent antipsychotic phenothiazine on a milligram basis (t1/2=15 to 30hours), containing a piperazine side chain that reduces anticholinergic effects while increasing EPS risk.

Fluphenazine Decanoate
A lipid-soluble fatty acid ester prodrug of fluphenazine formulated for long-acting depot IM injection (t1/2=6.8 to 9.6days), hydrolysable by blood esterases.
Butyrophenones
A class of high-potency typical antipsychotic agents (e.g., Haloperidol) characterized by strong affinity for D2 receptors and a high incidence of extrapyramidal side effects.
Haloperidol
A potent butyrophenone antipsychotic (1mg is equivalent to 50mg chlorpromazine; t1/2=10 to 30hours) used in schizophrenia, psychoses from brain damage, and mania termination, but associated with high EPS.
Haloperidol Lactate
A polar, hydrophilic salt formulation of haloperidol combined with lactic acid, administered at 2 to 5mg via IM or IV injection.
Haldol Decanoate
A lipophilic ester prodrug of haloperidol administered as a depot IM injection in sesame oil every 2 to 4weeks (t1/2≈3weeks); it must never be administered IV.
Atypical Antipsychotic Agents
Second-generation antipsychotics that combine dopamine D2 receptor antagonism with serotonin 5-HT2A receptor antagonism, offering effective symptom control with a lower incidence of EPS.
Benzazepine Derivatives
A class of atypical antipsychotics featuring a 6-7-6 tricyclic ring system (e.g., Clozapine, Olanzapine, Quetiapine) that display low EPS and high affinity for 5-HT2A receptors relative to D2 receptors.

Aripiprazole
An atypical antipsychotic containing quinolinone and arylpiperazine groups that acts as a partial agonist at D2 receptors, featuring low EPS and an elimination half-life of 75hours.
Dehydroaripiprazole
The active metabolite of aripiprazole generated via CYP3A4 and CYP2D6 oxidation, possessing an elimination half-life of 94hours.
Lithium Salts
Antimanic agents (specifically Lithium Carbonate and Lithium Citrate) that mimic sodium ions to enter sodium pump pathways without maintaining membrane potential, thereby preventing excessive neurotransmitter release in bipolar disorder.